表紙
市場調查報告書
商品編碼
1035794

新藥復溶系統市場:按容器類型(藥筒、輸液袋、預充式註射器)、按材料(玻璃、塑料)、按註射器和藥筒內藥物(液體、粉末)的物理條件、輸液袋內藥物 按物理狀態

Novel Drug Reconstitution Systems Market by Type of Container (Cartridge, Infusion Bag, Prefilled Syringe), Fabrication Material (Glass, Plastic), Physical State of Drug in Syringe and Cartridge (Liquid, Powder), Physical State of Drug in Infusion Bag

出版日期: | 出版商: Roots Analysis | 英文 325 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

視覺

近年來,市場上出現了眾多生物製藥和小分子藥物。許多這些生物製劑作為液體製劑不穩定,並且隨著藥代動力學和藥效學特性的變化往往會失去其有效性,從而難以長期儲存。冷凍乾燥已成為製造具有更長保質期的乾燥生物藥物製劑的首選方法。隨著此類藥物的廣泛使用,對能夠將凍乾藥物與稀釋劑適當混合併按所需量給藥的重建系統的需求不斷增加。

本報告探討了新藥重建系統的全球市場,並按容器類型、材料、注射器和藥筒中藥物的物理條件以及輸液袋中藥物的物理狀態對市場進行了概述。 、區域趨勢以及進入市場的公司概況。

目錄

第一章前言

  • 調查範圍
  • 調查方法
  • 重要問題得到解答
  • 本章概述

第 2 章執行摘要

第 3 章介紹

  • 本章概述
  • 重構系統概述
    • 藥物重組的重要考慮因素
  • 醫藥產品的冷凍乾燥
    • 需要重新配置系統
    • 雙室/多室系統
    • 一步重構系統
    • 傳統重構系統
  • 藥物重組系統的好處
    • 對製藥公司的好處
    • 對患者的好處
  • 結論

第四章市場情況:新藥重構體系

  • 本章概述
  • 新藥重組系統:產品線
  • 新藥重構體系:開發商的處境

第五章市場情況:其他重構系統

  • 本章概述
  • 一步重構系統:產品流水線
  • 一步重構系統:開發者情況
  • 傳統重構裝置:開發流水線
  • 傳統重配置設備:開發者情況

第六章公司簡介

  • 本章概述
  • 位於北美的主要參與者
    • 巴克斯特
    • ICU 醫療
  • 歐洲主要參與者
    • B.布勞恩
    • 維特製藥
  • 亞太地區的主要參與者
    • 尼普羅
    • 肖特-凱莎

第七章獲批藥品包裝趨勢分析

  • 本章概述
  • 範圍和研究方法
  • 批准藥品目錄(2014-2021年上半年)
  • 批准藥品的初級包裝
  • 關閉已批准藥品的初級包裝
  • 獲批藥品包裝趨勢分析:開發商情況
  • 結論

第八章專利分析

  • 本章概述
  • 範圍和研究方法
  • 新藥重構系統:專利分析
  • 新藥重構系統:專利基準分析
  • 新藥重構系統:專利評價分析
  • 按引用次數劃分的主要專利

第九章企業競爭力分析

  • 本章概述
  • 假設/主要參數
  • 調查方法
  • 企業競爭力分析:北美新藥重構系統廠商
  • 企業競爭力分析:歐洲新藥重構系統廠商
  • 企業競爭力分析:亞太及其他地區新藥重組系統廠商

第10章世界事件分析

  • 本章概述
  • 範圍和研究方法
  • 與新藥重組系統相關的全球事件

第11章SWOT分析

  • 本章概述
  • 新藥重構系統:SWOT分析
    • SWOT 因素比較

第十二章需求分析

  • 本章概述
  • 範圍和研究方法
  • 2021-2030 年雙腔預充式註射器的全球需求
  • 2021-2030 年全球對雙室墨盒的需求
  • 2021-2030 年全球對雙腔/多腔注射袋的需求
  • 結論

第十三章市場預測與機會分析

  • 本章概述
  • 研究方法和重要假設
  • 2021-2030 年全球雙腔預充式註射器市場
  • 2021-2030 年全球雙室墨盒市場
  • 2021-2030年全球雙/多腔注射袋市場
  • 2021-2030 年全球雙/多腔注射袋市場:區域分佈

第14章醫藥趨勢的未來趨勢

  • 本章概述
  • 承諾使用最新的給藥設備進行自我藥物治療
  • 創新包裝容器的開發
  • 對個性化治療的需求不斷增加
  • 雙腔系統與其他平台的集成
  • 增加發展中地區的行業舉措
  • 結論

第 15 章結論

第16章附錄1:匯總數據

第 17 章附錄 2:公司和組織名單

目錄

Title:
Novel Drug Reconstitution Systems
Market by Type of Container (Cartridge, Infusion Bag, Prefilled Syringe), Fabrication Material (Glass, Plastic), Physical State of Drug in Syringe and Cartridge (Liquid, Powder), Physical State of Drug in Infusion Bag (Liquid, Frozen), Volume of Container (<1 mL, 1-2.5 mL, 2.5-5 mL, >5 mL for prefilled syringe and cartridge; <250 mL, 250-500 mL, 500-1,000 mL, >1,000 mL for infusion bag), Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030.

VISUALS

Overview:

Over the last few years, numerous biologics and small molecule drugs have made their way to the market. Most of these biologic products are not stable as liquid formulations, and tend to lose efficacy with alterations in their pharmacokinetic and pharmacodynamic properties, thereby, making it difficult to preserve them for longer period of time. In order to achieve longer shelf life, lyophilization has emerged as the preferred choice for making dry biopharmaceutical formulations. In fact, around 30% of the FDA approved parenteral drugs are in lyophilized form. Since 2014, the FDA had approved more than 20 applications for lyophilized new drugs. Evidently, this method of producing stabilized formulations has witnessed widespread adoption and the affiliated market opportunity is estimated to be USD 3 billion. The increased adoption of such drugs has led to the rise in demand for reconstitution systems that allow proper mixing of lyophilized drug with the diluent and administration of required dose. The traditional reconstitution methods involve manual extraction and transfer of diluent into the vials containing the lyophilized product, using syringe and transfer needle. Given the large number of steps involved and multiple containers, this method is associated with the risk of medication errors and needle-stick injuries. In addition, the complexity associated with these conventional systems restricts the injection of lyophilized drugs only by the healthcare workers within the confined area of healthcare facilities.

The existing challenges in the conventional reconstitution method have prompted the pharmaceutical industry to develop advanced reconstitution devices, which allow the patients and caregivers to administer drugs without healthcare provider's intervention. These systems contain premeasured dose of drug and diluent, which essentially reduces the chances of dosing errors and needle-stick injuries. Moreover, these advanced systems enhance the portability, efficiency and optimum delivery of the lyophilized drugs and have the potential to reduce the number of steps significantly, which enable the dilution and reconstitution at the time of delivery. Owing to their multiple benefits, various pharmaceutical companies are considering these systems for lifecycle management of their drugs in order to enhance the provision of healthcare. Further, it is worth mentioning that over 1,800 patent applications have been filed / granted for reconstitution systems and affiliated technologies. We believe that such efforts are likely to drive growth in this market over the coming years.

Scope of the Report:

The 'Novel Drug Reconstitution Systems Market by Type of Container (Cartridge, Infusion Bag and Prefilled Syringe), Fabrication Material (Glass and Plastic), Physical State of Drug in Syringe and Cartridge (Liquid / Powder, Liquid / Liquid), Physical State of Drug in Infusion Bag (Liquid Mixture, Frozen Mixture), Volume of Container (<1 mL, 1-2.5 mL, 2.5-5 mL, >5 mL for prefilled syringe and cartridge; <250 mL, 250-500 mL, 500-1,000 mL, >1,000 mL for infusion bag), Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030' report features an extensive study on the current and future potential of novel drug reconstitution systems, being developed in order to ease the storage and administration of lyophilized drugs, thereby maintaining stability and shelf-life. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of novel drug reconstitution systems, providing information on the type of device (prefilled syringe, cartridge, infusion bags) , type of chamber (dual chamber, multi chamber) , physical state of drug (lyophilized, liquid) , container fabrication material (glass, plastic) , device usability (single use, multi-use) , and volume of container. In addition, the chapter includes details related to novel drug reconstitution system manufacturers, along with information on their year of establishment, company size, location of headquarters and key players (in terms of number of products manufactured) .
  • A detailed landscape of the reconstitution devices and systems featuring information on type of container or device, volume of primary container, physical state of drug, device usability and provision for self-administration. In addition, the chapter includes details related to the manufacturers, along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of prominent players engaged in this domain. Each profile includes a brief overview of the company, details related to its financial information (if available), information on product portfolio, recent developments and an informed future outlook.
  • A detailed analysis on the trends in packaging of over 350 drug products (including both biologics and small molecule drugs) that were approved by the FDA between 2014 and H1 2021, featuring an assessment of the packaging requirements of various container-closure systems based on several parameters, such as year of approval of drug, type of molecule (small molecule, biologic) , type of biologic (allogeneic cell therapy, autologous cell therapy, fusion proteins, hormones, interferons, monoclonal antibodies, recombinant enzymes, recombinant protein and viral cell therapy), type of primary packaging container used (vials, pouches / packets, bottles, IV / sealed bags, prefilled syringes / pen , tubes, cartridge, blister packaging, others), type of packaging material(s) used for manufacturing primary container, type of closure used (cap / needle shield, seal, plunger, stopper and others), type of packaging material(s) used for manufacturing closures, dosage form, route of administration, holding temperature. In addition, the chapter provides information on the developers of the aforementioned drugs and an analysis based on year of establishment, company size, location of headquarters and leading drug developers (in terms of number of drugs approved).
  • An insightful analysis of the patents filed / granted for novel drug reconstitution systems, since 2011, taking into consideration various relevant parameters, such as type of patent, publication year, geographical location, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
  • A competitiveness analysis of novel drug reconstitution system manufacturers based on various relevant parameters, such as supplier power (in terms of experience / expertise of the manufacturer) and key product specifications (number of systems, type of systems, type of drugs and number of chambers).
  • An in-depth analysis of recent events (summits / forums / conferences / annual meetings) that were organized for stakeholders in this domain, highlighting the evolution of discussion topics related to novel drug reconstitution systems. The analysis also provides details on type of event, regional distribution, emerging agendas, popular organizers, active industry and non-industry players, and a schematic mapping of upcoming events.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall novel drug reconstitution systems market.
  • An in-depth analysis to estimate the current and future demand for various novel drug reconstitution systems, including cartridges, infusion bags and prefilled syringes.
  • An elaborate discussion on emerging trends that are likely to have an impact on the future adoption of novel drug reconstitution systems. It presents a Harvey ball analysis, highlighting the relative effect of each trend on the adoption of novel drug reconstitution systems including dual chamber systems.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for novel drug reconstitution systems, over the next decade. Based on various parameters, such as target consumer segments, likely adoption rates and expected prices of such products, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of reconstitution system (prefilled syringe / cartridge / infusion bag), [B] physical state of drug (liquid / powder, liquid / liquid for prefilled syringes and cartridges; liquid mixture and frozen mixture for infusion bags), [C] type of fabrication material (glass, plastic / type of plastic for infusion bags), [D] volume of container (<1 mL, 1-2.5 mL, 2.5-5 mL and >5 mL for prefilled syringes and cartridges; 0-250 mL, 250-500 mL, 500-1,000 mL and >1,000 mL for infusion bags), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa) . In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the key players engaged in the development of novel drug reconstitution systems?
  • What is the relative competitiveness of different novel drug reconstitution system manufacturers?
  • What is the packaging trend in terms of container and closure for the drugs approved since 2014?
  • Who are the leading players focused on the development of lyophilized drugs?
  • What is the focus area of various conferences conducted in this domain?
  • How has the intellectual property landscape in this domain evolved over the years?
  • What are the emerging trends related to pharmaceutical packaging?
  • What are the key agenda items being discussed in various global events / conferences held in this domain?
  • How is the current and future market opportunity, likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the novel drug reconstitution systems market and its likely evolution in the short-mid to long term.

Chapter 3 provides a general introduction to novel drug reconstitution systems. In this chapter, we have briefly discussed the key considerations in reconstitution and the factors affecting reconstitution of drugs. The chapter also discusses the process of lyophilization of pharmaceuticals and need for reconstitution systems. In addition, it provides information on dual chamber systems and the benefits offered by these systems.

Chapter 4 presents an overview of the current market landscape of novel drug reconstitution systems, along with information on the type of device (prefilled syringe, cartridge, infusion bags), type of chamber (dual chamber, multi chamber) , physical state of drug (lyophilized, liquid), container fabrication material (glass, plastic), device usability (single use, multi-use), and volume of container. It also includes a detailed analysis based on the year of establishment, company size (in terms of employee count), region and location of headquarters. In addition, the chapter provides information on the novel drug reconstitution system manufacturers, while highlighting the leading players in this domain.

Chapter 5 presents an overview of the current market landscape of other reconstitution devices and systems (one step reconstitution systems and conventional reconstitution devices), along with information on the type of primary container, volume of primary container, physical state of drug, device usability and provision for self-administration. The chapter also provides information on the manufacturers of other reconstitution systems, along with analysis based on their year of establishment, company size, location of headquarters and leading players (in terms of number of products manufactured).

Chapter 6 includes profiles of the key players engaged in the development of novel drug reconstitution systems (shortlisted on the basis of the company size and the number of products in the pipeline). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.

Chapter 7 provides a detailed review of the packaging trends of over 350 product candidates (biologics and small molecule drugs) that were approved by the FDA between 2014 and H1 2021, including an analysis of the packaging requirements based on several relevant parameters, such as approval year of drug, type of molecule (small molecule, biologic), type of biologic (allogeneic cell therapy, autologous cell therapy, fusion proteins, hormones, interferons, monoclonal antibodies, recombinant enzymes, recombinant protein and viral cell therapy) , type of primary packaging container used (vials, pouches / packets, bottles, IV / sealed bags, prefilled syringes / pen , tubes, cartridge, blister packaging, others), most popular packaging material(s) used for primary containers, type of primary packaging closure used (cap / needle shield, seal, plunger, stopper and others), most popular packaging material(s) used for manufacturing closures, dosage form, route of administration, holding temperature. Further, the chapter provides information on the developers of the approved drugs, along with information on their year of establishment, company size, location of headquarters and most active players (in terms of number of small molecule drugs and number and type of biologics approved).

Chapter 8 features an in-depth analysis of the patents that have been filed / granted for the novel drug reconstitution systems, since 2011. The analysis also highlights the key trends associated with the patents, such as the type of patent (granted patent, patent application and others), publication year, application year, geographical location, CPC symbols, emerging focus areas of the patents, type of organization and leading players (in terms of number of patents granted / filed). In addition, it includes detailed patent benchmarking and valuation analysis based on patent characteristics.

Chapter 9 provides a competitiveness analysis of novel drug reconstitution system manufacturers that we came across during our research, based on supplier strength (in terms of experience / expertise of the manufacturer) and key product specifications (number of systems, type of systems, type of drugs and number of chambers).

Chapter 10 provides an analysis of recent events (summits / forums / conferences / workshops) related to novel drug reconstitution systems that were organized / planned. It features an analysis based on the year of occurrence of event, event platform, type of event, regional distribution, emerging agendas / key focus areas, most active event organizers, most active event speakers and geographical mapping of the upcoming events.

Chapter 11 provides information on the affiliated trends, key drivers and challenges associated with novel drug reconstitution systems, under a reliable SWOT framework. The chapter includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall novel drug reconstitution systems market.

Chapter 12 features a detailed analysis on the current and future demand for novel drug reconstitution systems. We have provided inputs on the likely demand for these systems across the type of reconstitution system (prefilled syringe / cartridge / infusion bag), physical state of drug (liquid / powder, liquid / liquid for prefilled syringes and cartridges; liquid mixture and frozen mixture for infusion bags), type of fabrication material (glass, plastic / type of plastic for infusion bags), volume of container (<1 mL, 1-2.5 mL, 2.5-5 mL and >5 mL for prefilled syringes and cartridges; 0-250 mL, 250-500 mL, 500-1,000 mL and >1,000 mL for infusion bags) geography (North America, Europe, Asia-Pacific, Latin America and Middle East and Africa) for the period, 2021-2030.

Chapter 13 features a detailed market forecast of the likely growth of novel drug reconstitution systems, till the year 2030. We have generated insights on the likely distribution of the current and forecasted opportunity across the type of reconstitution system (prefilled syringe / cartridge / infusion bag), physical state of drug (liquid / powder, liquid / liquid for prefilled syringes and cartridges; liquid mixture and frozen mixture for infusion bags), type of fabrication material (glass, plastic / type of plastic for infusion bags), volume of container (<1 mL, 1-2.5 mL, 2.5-5 mL and >5 mL for prefilled syringes and cartridges; 0-250 mL, 250-500 mL, 500-1,000 mL and >1,000 mL for infusion bags) , and key geographical regions (North America, Europe, Asia-Pacific, Latin America and Middle East and Africa) .

Chapter 14 provides information on the upcoming emerging trends (including preference for self-medication of drugs, shift towards more flexible packaging, focus on personalized therapies, integrating dual chamber systems with other platforms, and increase in the initiatives undertaken by industry stakeholders) that are likely to have an impact on the future adoption of novel drug reconstitution systems. It also presents a Harvey ball analysis, highlighting the relative impact of each trend on the adoption of novel drug reconstitution systems including dual chamber systems.

Chapter 15 is a summary of the overall report, presenting insights on the contemporary market trends and the likely evolution of the novel drug reconstitution systems market.

Chapter 16 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, that contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Reconstitution Systems
    • 3.2.1. Key Considerations in Drug Reconstitution
  • 3.3. Lyophilization of Pharmaceuticals
    • 3.3.1. Need for Reconstitution Systems
    • 3.3.2. Dual Chamber / Multi Chamber Systems
    • 3.3.3. One Step Reconstitution Systems
    • 3.3.4. Conventional Reconstitution Systems
  • 3.4. Advantages of Drug Reconstitution Systems
    • 3.4.1. Benefits to Pharmaceutical Players
    • 3.4.2. Benefits to Patients
  • 3.5. Concluding Remarks

4. MARKET LANDSCAPE: NOVEL DRUG RECONSTITUTION SYSTEMS

  • 4.1. Chapter Overview
  • 4.2. Novel Drug Reconstitution Systems: Product Pipeline
    • 4.2.1. Analysis by Type of Device
    • 4.2.2. Analysis by Type of Chamber
    • 4.2.3. Analysis by Type of Device and Type of Chamber
    • 4.2.4. Analysis by Physical State of Drug
    • 4.2.5. Analysis by Container Fabrication Material
    • 4.2.6. Analysis by Device Usability
    • 4.2.7. Analysis by Container Fabrication Material and Device Usability
    • 4.2.8. Analysis by Volume of Container
  • 4.3. Novel Drug Reconstitution Systems: Developer Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Region of Headquarters
    • 4.3.4. Analysis by Company Size and Region of Headquarters
    • 4.3.5. Analysis by Location of Headquarters
    • 4.3.6. Leading Players: Analysis by Number of Novel Drug Reconstitution Systems Manufactured

5. MARKET LANDSCAPE: OTHER RECONSTITUTION SYSTEMS

  • 5.1. Chapter Overview
  • 5.2. One Step Reconstitution Systems: Product Pipeline
    • 5.2.1. Analysis by Type of Primary Container
    • 5.2.2. Analysis by Volume of Primary Container
    • 5.2.3. Analysis by Physical State of Drug
    • 5.2.4. Analysis by Device Usability
    • 5.2.5. Analysis by Type of Primary Container and Physical State of Drug
  • 5.3. One Step Reconstitution Systems: Developer Landscape
    • 5.3.1. Analysis by Year of Establishment
    • 5.3.2. Analysis by Company Size
    • 5.3.3. Analysis by Location of Headquarters
    • 5.3.4. Leading Players: Analysis by Number of One Step Reconstitution Systems Manufactured
  • 5.4. Conventional Reconstitution Devices: Development Pipeline
    • 5.4.1. Analysis by Status of Development
    • 5.4.2. Analysis by Type of Device
    • 5.4.3. Analysis by Type of Primary Container
    • 5.4.4. Analysis by Physical State of Drug
    • 5.4.5. Analysis by Type of Primary Container and Physical State of Drug
  • 5.5. Conventional Reconstitution Devices: Developer Landscape
    • 5.5.1. Analysis by Year of Establishment
    • 5.5.2. Analysis by Company Size
    • 5.5.3. Analysis by Location of Headquarters
    • 5.5.4. Analysis by Region of Headquarters
    • 5.5.5. Leading Players: Analysis by Number of Conventional Reconstitution Devices Manufactured

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Key Players based in North America
    • 6.2.1. Baxter
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Information
      • 6.2.1.3. Product Portfolio
      • 6.2.1.4. Recent Developments and Future Outlook
    • 6.2.2. ICU Medical
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Information
      • 6.2.2.3. Product Portfolio
      • 6.2.2.4. Recent Developments and Future Outlook
  • 6.3. Key Players based in Europe
    • 6.3.1. B. Braun
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Financial Information
      • 6.3.1.3. Product Portfolio
      • 6.3.1.4. Recent Developments and Future Outlook
    • 6.3.2. Vetter Pharma
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Product Portfolio
      • 6.3.2.3. Recent Developments and Future Outlook
  • 6.4. Key Players based in Asia-Pacific
    • 6.4.1. Nipro
      • 6.4.1.1. Company Overview
      • 6.4.1.2. Financial Information
      • 6.4.1.3. Product Portfolio
      • 6.4.1.4. Recent Developments and Future Outlook
    • 6.4.2. SCHOTT-KAISHA
      • 6.4.2.1. Company Overview
      • 6.4.2.2. Product Portfolio
      • 6.4.2.3. Recent Developments and Future Outlook

7. PACKAGING TREND ANALYSIS FOR APPROVED DRUGS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. List of Approved Drugs (2014-H1 2021)
    • 7.3.1. Analysis by Type of Molecule and Approval Year
    • 7.3.2. Analysis by Type of Molecule
    • 7.3.3. Analysis by Type of Biologic
    • 7.3.4. Analysis by Type of Molecule and Holding Temperature
    • 7.3.5. Analysis by Type of Biologic and Dosage Form
  • 7.4. Primary Packaging Containers for Approved Drugs
    • 7.4.1. Analysis by Type of Primary Packaging Container
    • 7.4.2. Analysis by Type of Primary Packaging Container and Approval Year
    • 7.4.3. Analysis by Type of Primary Packaging Container and Type of Molecule
    • 7.4.4. Analysis by Type of Primary Packaging Container and Holding Temperature Range
    • 7.4.5. Analysis by Type of Primary Packaging Container and Dosage Form
    • 7.4.6. Analysis by Type of Primary Packaging Container and Route of Administration
    • 7.4.7. Most Popular Materials Used for Containers: Analysis by Number of Drugs
  • 7.5. Primary Packaging Closures for Approved Drugs
    • 7.5.1. Analysis by Type of Primary Packaging Closure
    • 7.5.2. Analysis by Type of Primary Packaging Closure and Approval Year
    • 7.5.3. Analysis by Type of Primary Packaging Closure and Type of Molecule
    • 7.5.4. Analysis by Type of Primary Packaging Closure and Holding Temperature Range
    • 7.5.5. Analysis by Type of Primary Packaging Closure and Dosage Form
    • 7.5.6. Analysis by Type of Primary Packaging Closure and Route of Administration
    • 7.5.7. Most Popular Materials Used for Closures: Analysis by Number of Drugs
  • 7.6. Packaging Trend Analysis for Approved Drugs: Developer Landscape
    • 7.6.1. Analysis by Year of Establishment
    • 7.6.2. Analysis by Company Size
    • 7.6.3. Analysis by Location of Headquarters
    • 7.6.4. Analysis by Type of Molecules and Company Size
    • 7.6.5. Analysis by Type of Molecule and Geographical Location of Developers
    • 7.6.6. Analysis by Type of Biologics and Geographical Location of Developers
    • 7.6.7. Most Active Players: Analysis by Type of Molecule
    • 7.6.8. Most Active Players: Analysis by Number of Biologics Developed
    • 7.6.9. Most Active Players: Analysis by Type of Biologic
    • 7.6.10. Most Active Players: Analysis by Number of Small Molecules Developed
  • 7.7. Concluding Remarks

8. PATENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Novel Drug Reconstitution Systems: Patent Analysis
    • 8.3.1. Analysis by Publication Year
    • 8.3.2. Analysis by Application Year
    • 8.3.3. Analysis by Geographical Location
    • 8.3.4. Analysis by CPC Symbols
    • 8.3.5. Word Cloud: Emerging Focus Areas
    • 8.3.6. Analysis by Type of Organization
    • 8.3.7. Leading Players: Analysis by Number of Patents
  • 8.4. Novel Drug Reconstitution Systems: Patent Benchmarking Analysis
    • 8.4.1. Analysis by Patent Characteristics
  • 8.5. Novel Drug Reconstitution Systems: Patent Valuation Analysis
  • 8.6. Leading Patents by Number of Citations

9. COMPANY COMPETITIVENESS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Assumptions / Key Parameters
  • 9.3. Methodology
  • 9.4. Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in North America
  • 9.5. Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Europe
  • 9.6. Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Asia-Pacific and Rest of the World

10. GLOBAL EVENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Global Events related to Novel Drug Reconstitution Systems
    • 10.3.1. Analysis by Year of Event
    • 10.3.2. Analysis by Event Platform
    • 10.3.3. Analysis by Type of Event
    • 10.3.4. Analysis by Geography
    • 10.3.5. Word Cloud: Evolutionary Trends in Event Agenda / Key Focus Area
    • 10.3.6. Most Active Event Organizers
    • 10.3.7. Most Active Participants: Analysis by Number of Events
    • 10.3.8. Analysis by Seniority Level of Participants
    • 10.3.9. Most Active Speakers: Analysis by Number of Events
    • 10.3.10. Geographical Mapping of Upcoming Events

11. SWOT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Novel Drug Reconstitution Systems: SWOT Analysis
    • 11.2.1. Comparison of SWOT Factors

12. DEMAND ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Global Demand for Dual Chamber Prefilled Syringes, 2021-2030
    • 12.3.1. Analysis by Physical State of Drug
      • 12.3.1.1. Global Demand of Dual Chamber Prefilled Syringes for Liquid / Powder Drugs, 2021-2030
      • 12.3.1.2. Global Demand of Dual Chamber Prefilled Syringes for Liquid / Liquid Drugs, 2021-2030
    • 12.3.2. Analysis by Type of Fabrication Material
      • 12.3.2.1. Global Demand for Glass Dual Chamber Prefilled Syringes, 2021-2030
      • 12.3.2.2. Global Demand for Plastic Dual Chamber Prefilled Syringes, 2021-2030
    • 12.3.3. Analysis by Volume
      • 12.3.3.1. Global Demand for <1 mL Dual Chamber Prefilled Syringes, 2021-2030
      • 12.3.3.2. Global Demand for 1-2.5 mL Dual Chamber Prefilled Syringes, 2021-2030
      • 12.3.3.3. Global Demand for 2.5-5 mL Dual Chamber Prefilled Syringes, 2021-2030
      • 12.3.3.4. Global Demand for >5 mL Dual Chamber Prefilled Syringes, 2021-2030
    • 12.3.4. Analysis by Geography
      • 12.3.4.1. Global Demand of Dual Chamber Prefilled Syringes in North America, 2021-2030
      • 12.3.4.2. Global Demand of Dual Chamber Prefilled Syringes in Europe, 2021-2030
      • 12.3.4.3. Global Demand of Dual Chamber Prefilled Syringes in Asia-Pacific, 2021-2030
      • 12.3.4.4. Global Demand of Dual Chamber Prefilled Syringes in Latin America, 2021-2030
      • 12.3.4.5. Global Demand of Dual Chamber Prefilled Syringes in Middle East and Africa, 2021-2030
  • 12.4. Global Demand for Dual Chamber Cartridges, 2021-2030
    • 12.4.1. Analysis by Physical State of Drug
      • 12.4.1.1. Global Demand of Dual Chamber Cartridges for Liquid / Powder Drugs, 2021-2030
      • 12.4.1.2. Global Demand of Dual Chamber Cartridges for Liquid / Liquid Drugs, 2021-2030
    • 12.4.2. Analysis by Type of Fabrication Material
      • 12.4.2.1. Global Demand for Glass Dual Chamber Cartridges, 2021-2030
      • 12.4.2.2. Global Demand for Plastic Dual Chamber Cartridges, 2021-2030
    • 12.4.3. Analysis by Volume
      • 12.4.3.1. Global Demand for <1 mL Dual Chamber Cartridges, 2021-2030
      • 12.4.3.2. Global Demand for 1-2.5 mL Dual Chamber Cartridges, 2021-2030
      • 12.4.3.3. Global Demand for 2.5-5 mL Dual Chamber Cartridges, 2021-2030
      • 12.4.3.4. Global Demand for >5 mL Dual Chamber Cartridges, 2021-2030
    • 12.4.4. Analysis by Geography
      • 12.4.4.1. Global Demand of Dual Chamber Cartridges in North America, 2021-2030
      • 12.4.4.2. Global Demand of Dual Chamber Cartridges in Europe, 2021-2030
      • 12.4.4.3. Global Demand of Dual Chamber Cartridges in Asia-Pacific, 2021-2030
      • 12.4.4.4. Global Demand of Dual Chamber Cartridges in Latin America, 2021-2030
      • 12.4.4.5. Global Demand of Dual Chamber Cartridges in Middle East and Africa, 2021-2030
      • 12.4.4.6. Global Demand of Dual Chamber Cartridges in Rest of the World, 2021-2030
  • 12.5. Global Demand for Dual / Multi Chamber Infusion Bags, 2021-2030
    • 12.5.1. Analysis by Physical State of Drug
      • 12.5.1.1. Global Demand of Dual / Multi Chamber Infusion Bags for Liquid Mixture, 2021-2030
      • 12.5.1.2. Global Demand of Dual / Multi Chamber Infusion Bags for Frozen Mixture, 2021-2030
    • 12.5.2. Analysis by Type of Plastic
      • 12.5.2.1. Global Demand of Ethylene Vinyl Acetate made Dual / Multi Chamber Infusion Bags, 2021-2030
      • 12.5.2.2. Global Demand of Polypropylene made Dual / Multi Chamber Infusion Bags, 2021-2030
      • 12.5.2.3. Global Demand of Polyvinyl Chloride made Dual / Multi Chamber Infusion Bags, 2021-2030
      • 12.5.2.4. Global Demand of Other Plastic made Dual / Multi Chamber Infusion Bags, 2021-2030
    • 12.5.3. Analysis by Volume
      • 12.5.3.1. Global Demand for 0-250 mL Dual / Multi Chamber Infusion Bags, 2021-2030
      • 12.5.3.2. Global Demand for 250-500 mL Dual / Multi Chamber Infusion Bags, 2021-2030
      • 12.5.3.3. Global Demand for 500-1,000 mL Dual / Multi Chamber Infusion Bags, 2021-2030
      • 12.5.3.4. Global Demand for >1,000 mL Dual / Multi Chamber Infusion Bags, 2021-2030
    • 12.5.4. Analysis by Geography
      • 12.5.4.1. Global Demand of Dual / Multi Chamber Infusion Bags in North America, 2021-2030
      • 12.5.4.2. Global Demand of Dual / Multi Chamber Infusion Bags in Europe, 2021-2030
      • 12.5.4.3. Global Demand of Dual / Multi Chamber Infusion Bags in Asia-Pacific, 2021-2030
      • 12.5.4.4. Global Demand of Dual / Multi Chamber Infusion Bags in Latin America, 2021-2030
      • 12.5.4.5. Global Demand of Dual / Multi Chamber Infusion Bags in Middle East and Africa, 2021-2030
  • 12.6. Concluding Remarks

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Methodology and Key Assumptions
  • 13.3. Global Dual Chamber Prefilled Syringes Market, 2021-2030
    • 13.3.1. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Physical State of Drug
      • 13.3.1.1. Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, 2021-2030
      • 13.3.1.2. Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, 2021-2030
    • 13.3.2. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Type of Fabrication Material Used
      • 13.3.2.1. Glass Dual Chamber Prefilled Syringes Market, 2021-2030
      • 13.3.2.2. Plastic Dual Chamber Prefilled Syringes Market, 2021-2030
    • 13.3.3. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
      • 13.3.3.1. Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030
      • 13.3.3.2. Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030
      • 13.3.3.3. Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, 2021-2030
      • 13.3.3.4. Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030
    • 13.3.4. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Geography
      • 13.3.4.1. Dual Chamber Prefilled Syringes Market in North America, 2021-2030
      • 13.3.4.2. Dual Chamber Prefilled Syringes Market in Europe, 2021-2030
      • 13.3.4.3. Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030
      • 13.3.4.4. Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030
      • 13.3.4.5. Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030
  • 13.4. Global Dual Chamber Cartridges Market, 2021-2030
    • 13.4.1. Dual Chamber Cartridges Market, 2021-2030: Distribution by Physical State of Drug
      • 13.4.1.1. Dual Chamber Cartridges Market for Liquid / Powder Drugs, 2021-2030
      • 13.4.1.2. Dual Chamber Cartridges Market for Liquid / Liquid Drugs, 2021-2030
    • 13.4.2. Dual Chamber Cartridges Market, 2021-2030: Distribution by Type of Fabrication Material Used
      • 13.4.2.1. Glass Dual Chamber Cartridges Market, 2021-2030
      • 13.4.2.2. Plastic Dual Chamber Cartridges Market, 2021-2030
    • 13.4.3. Dual Chamber Cartridges Market, 2021-2030: Distribution by Volume
      • 13.4.3.1. Dual Chamber Cartridges Market for <1 mL Cartridges, 2021-2030
      • 13.4.3.2. Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030
      • 13.4.3.3. Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, 2021-2030
      • 13.4.3.4. Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030
    • 13.4.4. Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
      • 13.4.4.1. Dual Chamber Cartridges Market in North America, 2021-2030
      • 13.4.4.2. Dual Chamber Cartridges Market in Europe, 2021-2030
      • 13.4.4.3. Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030
      • 13.4.4.4. Dual Chamber Cartridges Market in Latin America, 2021-2030
      • 13.4.4.5. Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030
      • 13.4.4.6. Dual Chamber Cartridges Market in Rest of the World, 2021-2030
  • 13.5. Global Dual / Multi Chamber Infusion Bags Market, 2021-2030
    • 13.5.1. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
      • 13.5.1.1. Dual / Multi Chamber Infusion Bags Market for Liquid Mixture, 2021-2030
      • 13.5.1.2. Dual / Multi Chamber Infusion Bags Market for Frozen Mixture, 2021-2030
    • 13.5.2. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic
      • 13.5.2.1. Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate, 2021-2030
      • 13.5.2.2. Dual / Multi Chamber Infusion Bags Market for Polypropylene, 2021-2030
      • 13.5.2.3. Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride, 2021-2030
      • 13.5.2.4. Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials, 2021-2030
    • 13.5.3. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
      • 13.5.3.1. Dual / Multi Chamber Infusion Bags Market for 0-250 mL Infusion Bags, 2021-2030
      • 13.5.3.2. Dual / Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, 2021-2030
      • 13.5.3.3. Dual / Multi Chamber Infusion Bags Market for 500-1,000 mL Infusion Bags, 2021-2030
      • 13.5.3.4. Dual / Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, 2021-2030
    • 13.5.4. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
      • 13.5.4.1. Dual / Multi Chamber Infusion Bags Market in North America, 2021-2030
      • 13.5.4.2. Dual / Multi Chamber Infusion Bags Market in Europe, 2021-2030
      • 13.5.4.3. Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030
      • 13.5.4.4. Dual / Multi Chamber Infusion Bags Market in Latin America, 2021-2030
      • 13.5.4.5. Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030

14. UPCOMING TRENDS IN PHARMACEUTICAL PACKAGING

  • 14.1. Chapter Overview
  • 14.2. Preference for Self-Medication of Drugs using Modern Drug Delivery Devices
  • 14.3. Development of Innovative Packaging Containers
  • 14.4. Growing Demand for Personalized Therapies
  • 14.5. Integrating Dual Chamber Systems with Other Platforms
  • 14.6. Increase in Initiatives Undertaken by Industry Stakeholders in Developing Regions
  • 14.7. Concluding Remarks

15. CONCLUDING REMARKS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 2.1 Executive Summary: Market Forecast
  • Figure 2.2 Executive Summary: Overall Market Landscape
  • Figure 2.3 Executive Summary: Packaging Trend Analysis for Approved Drugs
  • Figure 2.4 Executive Summary: Patent Analysis
  • Figure 2.5 Executive Summary: Global Event Analysis
  • Figure 2.6 Executive Summary: Demand Analysis
  • Figure 3.1 Basic Steps of Reconstitution
  • Figure 3.2 Factors Affecting Reconstitution of Drugs
  • Figure 3.3 Steps Involved in Lyophilization of Pharmaceuticals
  • Figure 3.4 Benefits of Reconstitution to Pharmaceutical Players
  • Figure 3.5 Benefits of Reconstitution to Patients
  • Figure 4.1 Novel Drug Reconstitution Systems: Distribution by Type of Device
  • Figure 4.2 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
  • Figure 4.3 Novel Drug Reconstitution Systems: Distribution by Type of Device and Type of Chamber
  • Figure 4.4 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
  • Figure 4.5 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
  • Figure 4.6 Novel Drug Reconstitution Systems: Distribution by Device Usability
  • Figure 4.7 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Device Usability
  • Figure 4.8 Novel Drug Reconstitution Systems: Distribution by Volume of Container
  • Figure 4.9 Novel Drug Reconstitution System Developers: Distribution by Year of Establishment
  • Figure 4.10 Novel Drug Reconstitution System Developers: Distribution by Company Size
  • Figure 4.11 Novel Drug Reconstitution System Developers: Distribution by Region of Headquarters
  • Figure 4.12 Novel Drug Reconstitution System Developers: Distribution by Company Size and Region of Headquarters
  • Figure 4.13 Novel Drug Reconstitution System Developers: Distribution by Location of Headquarters
  • Figure 4.14 Leading Players: Distribution by Number of Novel Drug Reconstitution Systems Manufactured
  • Figure 5.1 One Step Reconstitution Systems: Distribution by Type of Primary Container
  • Figure 5.2 One Step Reconstitution Systems: Distribution by Volume of Primary Container
  • Figure 5.3 One Step Reconstitution Systems: Distribution by Physical State of Drug
  • Figure 5.4 One Step Reconstitution Systems: Distribution by Device Usability
  • Figure 5.5 One Step Reconstitution Systems: Distribution by Type of Primary Container and Physical State of Drug
  • Figure 5.6 One Step Reconstitution System Developers: Distribution by Year of Establishment
  • Figure 5.7 One Step Reconstitution System Developers: Distribution by Company Size
  • Figure 5.8 One Step Reconstitution System Developers: Distribution by Location of Headquarters
  • Figure 5.9 Leading Players: Distribution by Number of One Step Reconstitution Systems Manufactured
  • Figure 5.10 Conventional Reconstitution Devices: Distribution by Status of Development
  • Figure 5.11 Conventional Reconstitution Devices: Distribution by Type of Device
  • Figure 5.12 Conventional Reconstitution Devices: Distribution by Type of Primary Container
  • Figure 5.13 Conventional Reconstitution Devices: Distribution by Physical State of Drug
  • Figure 5.14 Conventional Reconstitution Devices: Distribution by Type of Primary Container and Physical State of Drug
  • Figure 5.15 Conventional Reconstitution Device Developers: Distribution by Year of Establishment
  • Figure 5.16 Conventional Reconstitution Device Developers: Distribution by Company Size
  • Figure 5.17 Conventional Reconstitution Device Developers: Distribution by Location of Headquarters
  • Figure 5.18 Conventional Reconstitution Device Developers: Distribution of Manufacturers by Region of Headquarters
  • Figure 5.19 Leading Players: Distribution by Number of Conventional Reconstitution Devices Manufactured
  • Figure 6.1 Baxter: Annual Revenues, 2016-Q1 2021 (USD Billion)
  • Figure 6.2 ICU Medical: Annual Revenues, 2016-Q1 2021 (USD Billion)
  • Figure 6.3 B. Braun: Annual Revenues, 2016-FY 2020 (EUR Billion)
  • Figure 6.4 Nipro: Annual Revenues, 2016-FY 2021 (JPY Billion)
  • Figure 7.1 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Approval Year
  • Figure 7.2 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule
  • Figure 7.3 Approved Drugs (2014-H1 2021): Distribution by Type of Biologic
  • Figure 7.4 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Holding Temperature
  • Figure 7.5 Approved Drugs (2014-H1 2021): Distribution by Type of Biologic and Dosage Form
  • Figure 7.6 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container
  • Figure 7.7 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Approval Year
  • Figure 7.8 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Type of Molecule
  • Figure 7.9 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Holding Temperature Range
  • Figure 7.10 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Dosage Form
  • Figure 7.11 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Route of Administration
  • Figure 7.12 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Containers for Biologics
  • Figure 7.13 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Containers for Small Molecules
  • Figure 7.14 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure
  • Figure 7.15 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Approval Year
  • Figure 7.16 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Type of Molecule
  • Figure 7.17 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Holding Temperature Range
  • Figure 7.18 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Dosage Form
  • Figure 7.19 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Route of Administration
  • Figure 7.20 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Closures for Biologics
  • Figure 7.21 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Closures for Small Molecules
  • Figure 7.22 Approved Drug Developers: Distribution by Year of Establishment
  • Figure 7.23 Approved Drug Developers: Distribution by Company Size
  • Figure 7.24 Approved Drug Developers: Distribution by Location of Headquarters
  • Figure 7.25 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Company Size
  • Figure 7.26 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Geographical Location of Developers
  • Figure 7.27 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in North America
  • Figure 7.28 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in Europe
  • Figure 7.29 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in Asia-Pacific
  • Figure 7.30 Most Active Players: Distribution by Type of Molecule
  • Figure 7.31 Most Active Players: Distribution by Number of Biologics Developed
  • Figure 7.32 Most Active Players: Distribution by Type of Biologic
  • Figure 7.33 Most Active Players: Distribution by Number of Small Molecule Drugs Developed
  • Figure 7.34 Approved Drugs (2014-H1 2021), Grid Analysis: Distribution by Type of Container, Closure, Type of Material and Route of Administration
  • Figure 8.1 Patent Analysis: Distribution by Type of Patent
  • Figure 8.2 Patent Analysis: Cumulative Distribution by Publication Year, 2011-2021
  • Figure 8.3 Patent Analysis: Cumulative Distribution by Application Year, 2011-2021
  • Figure 8.4 Patent Analysis: Distribution by Geographical Location
  • Figure 8.5 Patent Analysis: Distribution by CPC Symbols
  • Figure 8.6 Word Cloud: Emerging Focus Areas
  • Figure 8.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2011-2021
  • Figure 8.8 Leading Players: Distribution by Number of Patents
  • Figure 8.9 Leading Individual Assignees: Distribution by Number of Patents
  • Figure 8.10 Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (CPC Symbols)
  • Figure 8.11 Patent Analysis: Year-wise Distribution of Patents by Age, 2001-2020
  • Figure 8.12 Novel Drug Reconstitution Systems: Patent Valuation Analysis
  • Figure 9.1 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in North America
  • Figure 9.2 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Europe
  • Figure 9.3 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Asia-Pacific and Rest of the World
  • Figure 10.1 Global Events: Cumulative Half Yearly Trend, H2 2015-H1 2022
  • Figure 10.2 Global Events: Distribution by Event Platform
  • Figure 10.3 Global Events: Distribution by Type of Event
  • Figure 10.4 Global Events: Distribution by Location of Event
  • Figure 10.5 Word Cloud: Evolutionary Trends in Event Agenda / Key Focus Area
  • Figure 10.6 Global Events: Historical Trend of Event Agendas, 2015-H1 2022
  • Figure 10.7 Global Events: Distribution by Event Organizers
  • Figure 10.8 Most Active Industry Participants: Distribution by Number of Events
  • Figure 10.9 Most Active Non-Industry Participants: Distribution by Number of Events
  • Figure 10.10 Global Events: Distribution by Designation of Participant
  • Figure 10.11 Global Events: Distribution by Affiliated Department of Participant
  • Figure 10.12 Most Active Speakers: Distribution by Number of Events
  • Figure 10.13 Global Events: Geographical Mapping of Upcoming Events
  • Figure 11.1 Novel Drug Reconstitution Systems: SWOT Analysis
  • Figure 11.2 SWOT Factors: Harvey Ball Analysis
  • Figure 12.1 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Figure 12.2 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Physical State of Drug
  • Figure 12.3 Global Demand for Dual Chamber Prefilled Syringes for Liquid / Powder Drugs, 2021-2030 (Billion Units)
  • Figure 12.4 Global Demand for Dual Chamber Prefilled Syringes for Liquid / Liquid Drugs, 2021-2030 (Billion Units)
  • Figure 12.5 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Type of Fabrication Material
  • Figure 12.6 Global Demand for Glass Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Figure 12.7 Global Demand for Plastic Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Figure 12.8 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Volume
  • Figure 12.9 Global Demand for <1 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Figure 12.10 Global Demand for 1-2.5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Figure 12.11 Global Demand for 2.5-5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Figure 12.12 Global Demand for >5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Figure 12.13 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Geography
  • Figure 12.14 Global Demand for Dual Chamber Prefilled Syringes in North America, 2021-2030 (Billion Units)
  • Figure 12.15 Global Demand for Dual Chamber Prefilled Syringes in Europe, 2021-2030 (Billion Units)
  • Figure 12.16 Global Demand for Dual Chamber Prefilled Syringes in Asia-Pacific, 2021-2030 (Billion Units)
  • Figure 12.17 Global Demand for Dual Chamber Prefilled Syringes in Latin America, 2021-2030 (Billion Units)
  • Figure 12.18 Global Demand for Dual Chamber Prefilled Syringes in Middle East and Africa, 2021-2030 (Billion Units)
  • Figure 12.19 Global Demand for Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Figure 12.20 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Physical State of Drug
  • Figure 12.21 Global Demand for Dual Chamber Cartridges for Liquid / Powder Drugs, 2021-2030 (Billion Units)
  • Figure 12.22 Global Demand for Dual Chamber Cartridges for Liquid / Liquid Drugs, 2021-2030 (Billion Units)
  • Figure 12.23 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Type of Fabrication Material
  • Figure 12.24 Global Demand for Glass Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Figure 12.25 Global Demand for Plastic Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Figure 12.26 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Volume
  • Figure 12.27 Global Demand for <1 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Figure 12.28 Global Demand for 1-2.5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Figure 12.29 Global Demand for 2.5-5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Figure 12.30 Global Demand for >5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Figure 12.31 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Geography
  • Figure 12.32 Global Demand for Dual Chamber Cartridges in North America, 2021-2030 (Billion Units)
  • Figure 12.33 Global Demand for Dual Chamber Cartridges in Europe, 2021-2030 (Billion Units)
  • Figure 12.34 Global Demand for Dual Chamber Cartridges in Asia-Pacific, 2021-2030 (Billion Units)
  • Figure 12.35 Global Demand for Dual Chamber Cartridges in Latin America, 2021-2030 (Billion Units)
  • Figure 12.36 Global Demand for Dual Chamber Cartridges in Middle East and Africa, 2021-2030 (Billion Units)
  • Figure 12.37 Global Demand for Dual Chamber Cartridges in Rest of the World, 2021-2030 (Billion Units)
  • Figure 12.38 Global Demand for Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Figure 12.39 Global Demand for Dual / Multi Chamber Infusion Bags, 2021-2030: Distribution by Physical State of Drug
  • Figure 12.40 Global Demand for Dual / Multi Chamber Infusion Bags for Liquid Mixture, 2021-2030 (Billion Units)
  • Figure 12.41 Global Demand for Dual / Multi Chamber Infusion Bags for Frozen Mixture, 2021-2030 (Billion Units)
  • Figure 12.42 Global Demand for Dual / Multi Chamber Infusion Bags, 2021-2030: Distribution by Type of Plastic
  • Figure 12.43 Global Demand for Ethylene Vinyl Acetate Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Figure 12.44 Global Demand for Polypropylene Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Figure 12.45 Global Demand for Polyvinyl Chloride Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Figure 12.46 Global Demand for Other Plastic Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Figure 12.47 Global Demand for Dual / Multi Chamber Infusion Bags, 2021-2030: Distribution by Volume
  • Figure 12.48 Global Demand for 0-250 mL Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Figure 12.49 Global Demand for 250-500 mL Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Figure 12.50 Global Demand for 500-1,000 mL Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Figure 12.51 Global Demand for >1,000 mL Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Figure 12.52 Global Demand for Dual / Multi Chamber Infusion Bags, 2021-2030: Distribution by Geography
  • Figure 12.53 Global Demand for Dual / Multi Chamber Infusion Bags in North America, 2021-2030 (Billion Units)
  • Figure 12.54 Global Demand for Dual / Multi Chamber Infusion Bags in Europe, 2021-2030 (Billion Units)
  • Figure 12.55 Global Demand for Dual / Multi Chamber Infusion Bags in Asia-Pacific, 2021-2030 (Billion Units)
  • Figure 12.56 Global Demand for Dual / Multi Chamber Infusion Bags in Latin America, 2021-2030 (Billion Units)
  • Figure 12.57 Global Demand for Dual / Multi Chamber Infusion Bags in Middle East and Africa, 2021-2030 (Billion Units)
  • Figure 13.1 Global Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
  • Figure 13.2 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Physical State of Drug
  • Figure 13.3 Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, 2021-2030 (USD Billion)
  • Figure 13.4 Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, 2021-2030 (USD Billion)
  • Figure 13.5 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Type of Fabrication Material Used
  • Figure 13.6 Glass Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
  • Figure 13.7 Plastic Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
  • Figure 13.8 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
  • Figure 13.9 Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030 (USD Billion)
  • Figure 13.10 Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030 (USD Billion)
  • Figure 13.11 Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, 2021-2030 (USD Billion)
  • Figure 13.12 Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030 (USD Billion)
  • Figure 13.13 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Geography
  • Figure 13.14 Dual Chamber Prefilled Syringes Market in North America, 2021-2030 (USD Billion)
  • Figure 13.15 Dual Chamber Prefilled Syringes Market in Europe, 2021-2030 (USD Billion)
  • Figure 13.16 Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030 (USD Billion)
  • Figure 13.17 Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030 (USD Billion)
  • Figure 13.18 Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030 (USD Billion)
  • Figure 13.19 Global Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
  • Figure 13.20 Dual Chamber Cartridges Market, 2021-2030: Distribution by Physical State of Drug
  • Figure 13.21 Dual Chamber Cartridges Market for Liquid / Powder Drugs, 2021-2030 (USD Billion)
  • Figure 13.22 Dual Chamber Cartridges Market for Liquid / Liquid Drugs, 2021-2030 (USD Billion)
  • Figure 13.23 Dual Chamber Cartridges Market, 2021-2030: Distribution by Type of Fabrication Material Used
  • Figure 13.24 Glass Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
  • Figure 13.25 Plastic Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
  • Figure 13.26 Dual Chamber Cartridges Market, 2021-2030: Distribution by Volume
  • Figure 13.27 Dual Chamber Cartridges Market for 1 mL Cartridges, 2021-2030 (USD Billion)
  • Figure 13.28 Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030 (USD Billion)
  • Figure 13.29 Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, 2021-2030 (USD Billion)
  • Figure 13.30 Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030 (USD Billion)
  • Figure 13.31 Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
  • Figure 13.32 Dual Chamber Cartridges Market in North America, 2021-2030 (USD Billion)
  • Figure 13.33 Dual Chamber Cartridges Market in Europe, 2021-2030 (USD Billion)
  • Figure 13.34 Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030 (USD Billion)
  • Figure 13.35 Dual Chamber Cartridges Market in Latin America, 2021-2030 (USD Billion)
  • Figure 13.36 Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030 (USD Billion)
  • Figure 13.37 Dual Chamber Cartridges Market in Rest of the World, 2021-2030 (USD Billion)
  • Figure 13.38 Global Dual / Multi Chamber Infusion Bags Market, 2021-2030 (USD Billion)
  • Figure 13.39 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
  • Figure 13.40 Dual / Multi Chamber Infusion Bags Market for Liquid Mixture, 2021-2030 (USD Billion)
  • Figure 13.41 Dual / Multi Chamber Infusion Bags Market for Frozen Mixture, 2021-2030 (USD Billion)
  • Figure 13.42 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic
  • Figure 13.43 Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate, 2021-2030 (USD Billion)
  • Figure 13.44 Dual / Multi Chamber Infusion Bags Market for Polypropylene, 2021-2030 (USD Billion)
  • Figure 13.45 Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride, 2021-2030 (USD Billion)
  • Figure 13.46 Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials, 2021-2030 (USD Billion)
  • Figure 13.47 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
  • Figure 13.48 Dual / Multi Chamber Infusion Bags Market for 0-250 mL Infusion Bags, 2021-2030 (USD Billion)
  • Figure 13.49 Dual / Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, 2021-2030 (USD Billion)
  • Figure 13.50 Dual / Multi Chamber Infusion Bags Market for 500-1,000 mL Infusion Bags, 2021-2030 (USD Billion)
  • Figure 13.51 Dual / Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, 2021-2030 (USD Billion)
  • Figure 13.52 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
  • Figure 13.53 Dual / Multi Chamber Infusion Bags Market in North America, 2021-2030 (USD Billion)
  • Figure 13.54 Dual / Multi Chamber Infusion Bags Market in Europe, 2021-2030 (USD Billion)
  • Figure 13.55 Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030 (USD Billion)
  • Figure 13.56 Dual / Multi Chamber Infusion Bags Market in Latin America, 2021-2030 (USD Billion)
  • Figure 13.57 Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030 (USD Billion)
  • Figure 14.1 Upcoming Trends Related to Pharmaceutical Packaging
  • Figure 14.2 Future Growth Opportunities of Dual Chamber Packaging Systems Based on Recent Trends
  • Figure 15.1 Concluding Remarks: Novel Drug Reconstitution Systems Market Landscape
  • Figure 15.2 Concluding Remarks: Other Reconstitution Systems Market Landscape
  • Figure 15.3 Concluding Remarks:Packaging Trend Analysis for Approved Drugs
  • Figure 15.4 Concluding Remarks: Patent Analysis
  • Figure 15.5 Concluding Remarks: Company Competitiveness Analysis
  • Figure 15.6 Concluding Remarks: Global Event Analysis
  • Figure 15.7 Concluding Remarks:Demand Analysis
  • Figure 15.8 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

  • Table 4.1 Novel Drug Reconstitution Systems: Information on Type of Product, Number of Chambers, Physical State of Drug and Product Certifications
  • Table 4.2 Novel Drug Reconstitution Systems: Information on Container Fabrication Material, Volume, Drug Class, Device Usability and Provisions for Self-Administration
  • Table 4.3 Novel Drug Reconstitution Systems: Developer Landscape
  • Table 5.1 One Step Reconstitution Systems: Information on Status of Development, Type of Primary Container, Volume and Product Certifications
  • Table 5.2 One Step Reconstitution Systems: Information on Physical State of Drug, Device Usability, Provisions for Self-Administration and Route of Administration
  • Table 5.3 One Step Reconstitution Systems: Developer Landscape
  • Table 5.4 Conventional Reconstitution Devices: Information on Status of Development, Type of Device, Type of Primary Container, Volume and Product Certifications
  • Table 5.5 Conventional Reconstitution Devices: Information on Physical State of Drug, Device Usability, Provisions for Self-Administration and Route of Administration
  • Table 5.6 Conventional Reconstitution Devices: Developer Landscape
  • Table 6.1 Novel Drug Reconstitution System Manufacturers: List of Companies Profiled
  • Table 6.2 Baxter: Company Snapshot
  • Table 6.3 Baxter: Product Portfolio
  • Table 6.4 Baxter: Recent Developments and Future Outlook
  • Table 6.5 ICU Medical: Company Snapshot
  • Table 6.6 ICU Medical: Product Portfolio
  • Table 6.7 ICU Medical: Recent Developments and Future Outlook
  • Table 6.8 B. Braun: Company Snapshot
  • Table 6.9 B. Braun: Product Portfolio
  • Table 6.10 B. Braun: Recent Developments and Future Outlook
  • Table 6.11 Vetter Pharma: Company Snapshot
  • Table 6.12 Vetter Pharma: Product Portfolio
  • Table 6.13 Vetter Pharma: Recent Developments and Future Outlook
  • Table 6.14 Nipro: Company Snapshot
  • Table 6.15 Nipro: Product Portfolio
  • Table 6.16 Nipro: Recent Developments and Future Outlook
  • Table 6.17 SCHOTT-KAISHA: Company Snapshot
  • Table 6.18 SCHOTT-KAISHA: Product Portfolio
  • Table 6.19 SCHOTT-KAISHA: Recent Developments and Future Outlook
  • Table 7.1 List of Approved Drugs (2014-H1 2021): Information on Dosage Form, Route of Administration and Holding Temperature Range
  • Table 7.2 List of Approved Drugs (2014-H1 2021): Information on Type of Container and Container Material
  • Table 7.3 List of Approved Drugs (2014-H1 2021): Information on Type of Closure and Closure Material
  • Table 8.1 Patent Analysis: CPC Symbol Definitions
  • Table 8.2 Patent Analysis: Popular CPC Symbols
  • Table 8.3 Patent Analysis: CPC Classification Symbol Definitions
  • Table 8.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 8.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 8.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
  • Table 8.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
  • Table 10.1 List of Global Events related to Novel Drug Reconstitution Systems
  • Table 16.1 Novel Drug Reconstitution Systems: Distribution by Type of Device
  • Table 16.2 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
  • Table 16.3 Novel Drug Reconstitution Systems: Distribution by Type of Device and Type of Chamber
  • Table 16.4 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
  • Table 16.5 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
  • Table 16.6 Novel Drug Reconstitution Systems: Distribution by Device Usability
  • Table 16.7 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Device Usability
  • Table 16.8 Novel Drug Reconstitution Systems: Distribution by Volume of Container
  • Table 16.9 Novel Drug Reconstitution System Developers: Distribution by Year of Establishment
  • Table 16.10 Novel Drug Reconstitution System Developers: Distribution by Company Size
  • Table 16.11 Novel Drug Reconstitution System Developers: Distribution by Region of Headquarters
  • Table 16.12 Novel Drug Reconstitution System Developers: Distribution by Company Size and Region of Headquarters
  • Table 16.13 Novel Drug Reconstitution System Developers: Distribution by Location of Headquarters
  • Table 16.14 Leading Players: Distribution by Number of Novel Drug Reconstitution Systems Manufactured
  • Table 16.15 One Step Reconstitution Systems: Distribution by Type of Primary Container
  • Table 16.16 One Step Reconstitution Systems: Distribution by Volume of Primary Container
  • Table 16.17 One Step Reconstitution Systems: Distribution by Physical State of Drug
  • Table 16.18 One Step Reconstitution Systems: Distribution by Device Usability
  • Table 16.19 One Step Reconstitution Systems: Distribution by Type of Primary Container and Physical State of Drug
  • Table 16.20 One Step Reconstitution System Developers: Distribution by Year of Establishment
  • Table 16.21 One Step Reconstitution System Developers: Distribution by Company Size
  • Table 16.22 One Step Reconstitution System Developers: Distribution by Location of Headquarters
  • Table 16.23 Leading Players: Distribution by Number of One Step Reconstitution Systems Manufactured
  • Table 16.24 Conventional Reconstitution Devices: Distribution by Status of Development
  • Table 16.25 Conventional Reconstitution Devices: Distribution by Type of Device
  • Table 16.26 Conventional Reconstitution Devices: Distribution by Type of Primary Container
  • Table 16.27 Conventional Reconstitution Devices: Distribution by Physical State of Drug
  • Table 16.28 Conventional Reconstitution Devices: Distribution by Type of Primary Container and Physical State of Drug
  • Table 16.29 Conventional Reconstitution Device Developers: Distribution by Year of Establishment
  • Table 16.30 Conventional Reconstitution Device Developers: Distribution by Company Size
  • Table 16.31 Conventional Reconstitution Device Developers: Distribution by Location of Headquarters
  • Table 16.32 Conventional Reconstitution Device Developers: Distribution by Region of Headquarters
  • Table 16.33 Leading Players: Distribution by Number of Conventional Reconstitution Devices Manufactured
  • Table 16.34 Baxter: Annual Revenues, 2016-Q1 2021 (USD Billion)
  • Table 16.35 ICU Medical: Annual Revenues, 2016-Q1 2021 (USD Billion)
  • Table 16.36 B. Braun: Annual Revenues, 2016-FY 2020 (EUR Billion)
  • Table 16.37 Nipro: Annual Revenues, 2016-FY 2021 (JPY Billion)
  • Table 16.38 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Approval Year
  • Table 16.39 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule
  • Table 16.40 Approved Drugs (2014-H1 2021): Distribution by Type of Biologic
  • Table 16.41 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Holding Temperature
  • Table 16.42 Approved Drugs (2014-H1 2021): Distribution by Type of Biologic and Dosage Form
  • Table 16.43 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container
  • Table 16.44 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Approval Year
  • Table 16.45 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Type of Molecule
  • Table 16.46 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Holding Temperature Range
  • Table 16.47 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Dosage Form
  • Table 16.48 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Container and Route of Administration
  • Table 16.49 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Containers for Biologics
  • Table 16.50 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Containers for Small Molecules
  • Table 16.51 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure
  • Table 16.52 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Approval Year
  • Table 16.53 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Type of Molecule
  • Table 16.54 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Holding Temperature Range
  • Table 16.55 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Dosage Form
  • Table 16.56 Approved Drugs (2014-H1 2021): Distribution by Type of Primary Packaging Closure and Route of Administration
  • Table 16.57 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Closures for Biologics
  • Table 16.58 Approved Drugs (2014-H1 2021): Popular Type of Material Used in Closures for Small Molecules
  • Table 16.59 Approved Drug Developers: Distribution by Year of Establishment
  • Table 16.60 Approved Drug Developers: Distribution by Company Size
  • Table 16.61 Approved Drug Developers: Distribution by Location of Headquarters
  • Table 16.62 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Company Size
  • Table 16.63 Approved Drugs (2014-H1 2021): Distribution by Type of Molecule and Geographical Location of Developers
  • Table 16.64 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in North America
  • Table 16.65 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in Europe
  • Table 16.66 Approved Drugs (2014-H1 2021): Distribution by Type of Biologics and Developers based in Asia-Pacific
  • Table 16.67 Most Active Players: Distribution by Type of Molecule
  • Table 16.68 Most Active Players: Distribution by Number of Biologics Developed
  • Table 16.69 Most Active Players: Distribution by Type of Biologic
  • Table 16.70 Most Active Players: Distribution by Number of Small Molecule Drugs Developed
  • Table 16.71 Approved Drugs (2014-H1 2021), Grid Analysis: Distribution by Type of Container, Closure, Type of Material and Route of Administration
  • Table 16.72 Patent Analysis: Distribution by Type of Patent
  • Table 16.73 Patent Analysis: Cumulative Distribution by Publication Year, 2011-2021
  • Table 16.74 Patent Analysis: Cumulative Distribution by Application Year, 2011-2021
  • Table 16.75 Patent Analysis: Distribution by Geographical Location
  • Table 16.76 Patent Analysis: Distribution by CPC Symbols
  • Table 16.77 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2011-2021
  • Table 16.78 Leading Players: Distribution by Number of Patents
  • Table 16.79 Leading Individual Assignees: Distribution by Number of Patents
  • Table 16.80 Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (CPC Symbols)
  • Table 16.81 Patent Analysis: Year-wise Distribution of Patents by Age, 2001-2020
  • Table 16.82 Novel Drug Reconstitution Systems: Patent Valuation Analysis
  • Table 16.83 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in North America
  • Table 16.84 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Europe
  • Table 16.85 Company Competitiveness Analysis: Novel Drug Reconstitution System Manufacturers in Asia-Pacific and Rest of the World
  • Table 16.86 Global Events: Cumulative Half Yearly Trend, H2 2015-H1 2022
  • Table 16.87 Global Events: Distribution by Event Platform
  • Table 16.88 Global Events: Distribution by Type of Event
  • Table 16.89 Global Events: Distribution by Location of Event
  • Table 16.90 Global Events: Distribution by Event Organizers
  • Table 16.91 Most Active Industry Participants: Distribution by Number of Events
  • Table 16.92 Most Active Non-Industry Participants: Distribution by Number of Events
  • Table 16.93 Global Events: Distribution by Designation of Participant
  • Table 16.94 Global Events: Distribution by Affiliated Department of Participant
  • Table 16.95 Most Active Speakers: Distribution by Number of Events
  • Table 16.96 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Table 16.97 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Physical State of Drug
  • Table 16.98 Global Demand for Dual Chamber Prefilled Syringes for Liquid / Powder Drugs, 2021-2030 (Billion Units)
  • Table 16.99 Global Demand for Dual Chamber Prefilled Syringes for Liquid / Liquid Drugs, 2021-2030 (Billion Units)
  • Table 16.100 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Type of Fabrication Material
  • Table 16.101 Global Demand for Glass Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Table 16.102 Global Demand for Plastic Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Table 16.103 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Volume
  • Table 16.104 Global Demand for <1 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Table 16.105 Global Demand for 1-2.5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Table 16.106 Global Demand for 2.5-5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Table 16.107 Global Demand for >5 mL Dual Chamber Prefilled Syringes, 2021-2030 (Billion Units)
  • Table 16.108 Global Demand for Dual Chamber Prefilled Syringes, 2021-2030: Distribution by Geography
  • Table 16.109 Global Demand for Dual Chamber Prefilled Syringes in North America, 2021-2030 (Billion Units)
  • Table 16.110 Global Demand for Dual Chamber Prefilled Syringes in Europe, 2021-2030 (Billion Units)
  • Table 16.111 Global Demand for Dual Chamber Prefilled Syringes in Asia-Pacific, 2021-2030 (Billion Units)
  • Table 16.112 Global Demand for Dual Chamber Prefilled Syringes in Latin America, 2021-2030 (Billion Units)
  • Table 16.113 Global Demand for Dual Chamber Prefilled Syringes in Middle East and Africa, 2021-2030 (Billion Units)
  • Table 16.114 Global Demand for Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Table 16.115 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Physical State of Drug
  • Table 16.116 Global Demand for Dual Chamber Cartridges for Liquid / Powder Drugs, 2021-2030 (Billion Units)
  • Table 16.117 Global Demand for Dual Chamber Cartridges for Liquid / Liquid Drugs, 2021-2030 (Billion Units)
  • Table 16.118 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Type of Fabrication Material
  • Table 16.119 Global Demand for Glass Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Table 16.120 Global Demand for Plastic Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Table 16.121 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Volume
  • Table 16.122 Global Demand for <1 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Table 16.123 Global Demand for 1-2.5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Table 16.124 Global Demand for 2.5-5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Table 16.125 Global Demand for >5 mL Dual Chamber Cartridges, 2021-2030 (Billion Units)
  • Table 16.126 Global Demand for Dual Chamber Cartridges, 2021-2030: Distribution by Geography
  • Table 16.127 Global Demand for Dual Chamber Cartridges in North America, 2021-2030 (Billion Units)
  • Table 16.128 Global Demand for Dual Chamber Cartridges in Europe, 2021-2030 (Billion Units)
  • Table 16.129 Global Demand for Dual Chamber Cartridges in Asia-Pacific, 2021-2030 (Billion Units)
  • Table 16.130 Global Demand for Dual Chamber Cartridges in Latin America, 2021-2030 (Billion Units)
  • Table 16.131 Global Demand for Dual Chamber Cartridges in Middle East and Africa, 2021-2030 (Billion Units)
  • Table 16.132 Global Demand for Dual Chamber Cartridges in Rest of the World, 2021-2030 (Billion Units)
  • Table 16.133 Global Demand for Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Table 16.134 Global Demand for Dual / Multi Chamber Infusion Bags, 2021-2030: Distribution by Physical State of Drug
  • Table 16.135 Global Demand for Dual / Multi Chamber Infusion Bags for Liquid Mixture, 2021-2030 (Billion Units)
  • Table 16.136 Global Demand for Dual / Multi Chamber Infusion Bags for Frozen Mixture, 2021-2030 (Billion Units)
  • Table 16.137 Global Demand for Dual / Multi Chamber Infusion Bags, 2021-2030: Distribution by Type of Plastic
  • Table 16.138 Global Demand for Ethylene Vinyl Acetate Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Table 16.139 Global Demand for Polypropylene Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Table 16.140 Global Demand for Polyvinyl Chloride Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Table 16.141 Global Demand for Other Plastic Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Table 16.142 Global Demand for Dual / Multi Chamber Infusion Bags, 2021-2030: Distribution by Volume
  • Table 16.143 Global Demand for 0-250 mL Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Table 16.144 Global Demand for 250-500 mL Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Table 16.145 Global Demand for 500-1,000 mL Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Table 16.146 Global Demand for >1,000 mL Dual / Multi Chamber Infusion Bags, 2021-2030 (Billion Units)
  • Table 16.147 Global Demand for Dual / Multi Chamber Infusion Bags, 2021-2030: Distribution by Geography
  • Table 16.148 Global Demand for Dual / Multi Chamber Infusion Bags in North America, 2021-2030 (Billion Units)
  • Table 16.149 Global Demand for Dual / Multi Chamber Infusion Bags in Europe, 2021-2030 (Billion Units)
  • Table 16.150 Global Demand for Dual / Multi Chamber Infusion Bags in Asia-Pacific, 2021-2030 (Billion Units)
  • Table 16.151 Global Demand for Dual / Multi Chamber Infusion Bags in Latin America, 2021-2030 (Billion Units)
  • Table 16.152 Global Demand for Dual / Multi Chamber Infusion Bags in Middle East and Africa, 2021-2030 (Billion Units)
  • Table 16.153 Global Dual Chamber Prefilled Syringes Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.154 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Physical State of Drug (USD Billion)
  • Table 16.155 Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.156 Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.157 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Type of Fabrication Material Used (USD Billion)
  • Table 16.158 Glass Dual Chamber Prefilled Syringes Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.159 Plastic Dual Chamber Prefilled Syringes Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.160 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume (USD Billion)
  • Table 16.161 Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.162 Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.163 Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.164 Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.165 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Geography (USD Billion)
  • Table 16.166 Dual Chamber Prefilled Syringes Market in North America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.167 Dual Chamber Prefilled Syringes Market in Europe, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.168 Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.169 Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.170 Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.171 Global Dual Chamber Cartridges Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.172 Dual Chamber Cartridges Market, 2021-2030: Distribution by Physical State of Drug (USD Billion)
  • Table 16.173 Dual Chamber Cartridges Market for Liquid / Powder Drugs, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.174 Dual Chamber Cartridges Market for Liquid / Liquid Drugs, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.175 Dual Chamber Cartridges Market, 2021-2030: Distribution by Type of Fabrication Material Used (USD Billion)
  • Table 16.176 Glass Dual Chamber Cartridges Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.177 Plastic Dual Chamber Cartridges Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.178 Dual Chamber Cartridges Market, 2021-2030: Distribution by Volume (USD Billion)
  • Table 16.179 Dual Chamber Cartridges Market for <1 mL Cartridges, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.180 Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.181 Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.182 Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.183 Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography (USD Billion)
  • Table 16.184 Dual Chamber Cartridges Market in North America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.185 Dual Chamber Cartridges Market in Europe, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.186 Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.187 Dual Chamber Cartridges Market in Latin America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.188 Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.189 Dual Chamber Cartridges Market in Rest of the World, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.190 Global Dual / Multi Chamber Infusion Bags Market, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.191 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug (USD Billion)
  • Table 16.192 Dual / Multi Chamber Infusion Bags Market for Liquid Mixture, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.193 Dual / Multi Chamber Infusion Bags Market for Frozen Mixture, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.194 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic (USD Billion)
  • Table 16.195 Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.196 Dual / Multi Chamber Infusion Bags Market for Polypropylene, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.197 Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.198 Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.199 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume (USD Billion)
  • Table 16.200 Dual / Multi Chamber Infusion Bags Market for 0-250 mL Infusion Bags, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.201 Dual / Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.202 Dual / Multi Chamber Infusion Bags Market for 500-1,000 mL Infusion Bags, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.203 Dual / Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.204 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography (USD Billion)
  • Table 16.205 Dual / Multi Chamber Infusion Bags Market in North America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.206 Dual / Multi Chamber Infusion Bags Market in Europe, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.207 Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.208 Dual / Multi Chamber Infusion Bags Market in Latin America, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 16.209 Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report.

  • 1. 3M Innovative Properties
  • 2. AbbVie
  • 3. Ablynx
  • 4. Acacia Pharma
  • 5. Acadia Pharmaceuticals
  • 6. AcelRx Pharmaceuticals
  • 7. Achaogen
  • 8. Acorda Therapeutics
  • 9. Actelion Pharmaceuticals
  • 10. ADC Therapeutics
  • 11. ADIENNE
  • 12. Advanced Accelerator Applications (AAA)
  • 13. AdvoCare Medical
  • 14. Aerie Pharmaceuticals
  • 15. Agios Pharmaceuticals
  • 16. Aguettant
  • 17. AkaRx (acquired by Eisai)
  • 18. Akcea Therapeutics (acquired by Ionis Pharmaceuticals)
  • 19. Alcon Laboratories
  • 20. Alexion Pharmaceuticals
  • 21. Alkermes
  • 22. Allergan
  • 23. Almirall
  • 24. Alnylam Pharmaceuticals
  • 25. AMAG Pharmaceuticals (acquired by Covis Pharma)
  • 26. Amgen
  • 27. Amivas
  • 28. Amphastar Pharmaceuticals
  • 29. Amsino
  • 30. Anacor Pharmaceuticals (acquired by Pfizer)
  • 31. Antares Pharma
  • 32. Apellis Pharmaceuticals
  • 33. Aquestive Therapeutics
  • 34. ARaymond
  • 35. Ardelyx
  • 36. ARIAD Pharmaceuticals (acquired by Takeda)
  • 37. Array BioPharma (acquired by Takeda)
  • 38. Arte
  • 39. Astellas Pharma
  • 40. AstraZeneca
  • 41. Aurinia Pharmaceuticals
  • 42. AVEO Pharmaceuticals
  • 43. B. Braun
  • 44. Bausch & Lomb
  • 45. Bausch Health Companies (formerly Valeant Pharmaceuticals)
  • 46. Baxter
  • 47. Bayer Healthcare
  • 48. Becton Dickinson (BD)
  • 49. BeiGene
  • 50. Biocorp
  • 51. BioCryst Pharmaceuticals
  • 52. Biogen
  • 53. Biohaven Pharmaceuticals
  • 54. BioMarin Pharmaceutical
  • 55. Bioprojet Pharma
  • 56. BloodWorks
  • 57. Blue Earth
  • 58. Blueprint Medicines
  • 59. Boehringer Ingelheim
  • 60. Bracco Diagnostics
  • 61. Braintree Laboratories (acquired by Sebela Pharmaceuticals )
  • 62. Bristol Myers Squibb
  • 63. Cassiopea
  • 64. Catalyst Pharmaceuticals
  • 65. Celgene
  • 66. Celltrion
  • 67. Chelsea Therapeutics
  • 68. Chemo Research
  • 69. Chiesi USA
  • 70. Cleveland Cord Blood Center (CCBC)
  • 71. CLINUVEL
  • 72. Clovis Oncology
  • 73. Cosmo Pharmaceuticals
  • 74. Credence Medsystems
  • 75. Cubist Pharmaceuticals
  • 76. Curium
  • 77. Daiichi Sankyo
  • 78. Debiotech
  • 79. Deciphera Pharmaceuticals
  • 80. Dr. Reddy's Laboratories
  • 81. Duoject
  • 82. Durata Therapeutics (acquired by Actavis)
  • 83. Dutch Ophthalmic Research Center
  • 84. Eiger BioPharmaceuticals
  • 85. Eisai
  • 86. Eli Lilly
  • 87. Elusys Therapeutics
  • 88. EMD Serono
  • 89. Enable Injections
  • 90. Epizyme
  • 91. Equashield
  • 92. Esperion Therapeutics
  • 93. Evolus
  • 94. ExEm Foam
  • 95. EyePoint Pharmaceuticals
  • 96. Ferrer
  • 97. Fresenius Kabi
  • 98. G1 Therapeutics
  • 99. Galderma
  • 100. Genentech
  • 101. Gerresheimer
  • 102. Gilead Sciences
  • 103. GlaxoSmithKline
  • 104. Global Blood Therapeutics
  • 105. Greenwich Biosciences
  • 106. Grifols
  • 107. Haemopharm
  • 108. Harmony Biosciences
  • 109. Helapet
  • 110. Helsinn Healthcare
  • 111. Hemedis
  • 112. Horizon Therapeutics
  • 113. ICU Medical
  • 114. IDEO
  • 115. iHealthNet
  • 116. Immunomedics (acquired by Gilead Sciences)
  • 117. Incyte
  • 118. Insmed
  • 119. Integrity Bio
  • 120. Intercept Pharmaceuticals
  • 121. Intra-Cellular Therapies
  • 122. Ionis Pharmaceuticals
  • 123. Ironwood Pharmaceuticals
  • 124. ITF Pharma
  • 125. Janssen Pharmaceuticals
  • 126. Jazz Pharmaceuticals
  • 127. JW Chemi Town
  • 128. KAI Pharmaceuticals (acquired by Amgen)
  • 129. Kapsam
  • 130. Karyopharm Therapeutics
  • 131. KemPharm
  • 132. Kite Pharma
  • 133. Kyowa Kirin
  • 134. Kythera Biopharma (acquired by Allergan)
  • 135. La Jolla Pharmaceutical Company
  • 136. Leadiant Biosciences
  • 137. Lexicon Pharmaceuticals
  • 138. Lundbeck
  • 139. Lupin
  • 140. MacroGenics
  • 141. Maeda Industry
  • 142. Mayne Pharma
  • 143. MEDIPHARMAPLAN
  • 144. Medicines Development for Global Health (MDGH)
  • 145. MedXL
  • 146. Melinta Therapeutics
  • 147. Merck
  • 148. Millennium Pharmaceuticals (acquired by Takeda)
  • 149. Miltenyi Biotec
  • 150. Mitsubishi Tanabe Pharma
  • 151. MorphoSys
  • 152. Myovant Sciences
  • 153. Mystic Pharmaceuticals
  • 154. Nabriva Therapeutics
  • 155. Neurocrine Biosciences
  • 156. Nipro
  • 157. Novartis
  • 158. Novimmune
  • 159. Novo Nordisk
  • 160. NPS Pharmaceuticals
  • 161. NS Pharma
  • 162. Nündel Kunststofftechnologie
  • 163. Ocular Therapeutix
  • 164. Oncopeptides
  • 165. Organon International
  • 166. Origin Biosciences
  • 167. Ortho Dermatologics
  • 168. Otsuka Pharmaceutical
  • 169. Paladin
  • 170. Paratek Pharmaceuticals
  • 171. Pfizer
  • 172. PHC Injection Device Technologies
  • 173. Piramal Imaging
  • 174. Portola Pharmaceuticals (acquired by Alexion Pharmaceuticals)
  • 175. Progenics Pharmaceuticals
  • 176. PTC Therapeutics
  • 177. Puma Biotechnology
  • 178. QED Therapeutics
  • 179. Radius Health
  • 180. Recon Therapeutics
  • 181. Recordati Rare Diseases
  • 182. Regeneron Pharmaceuticals
  • 183. Relypsa
  • 184. Rempex Pharmaceuticals
  • 185. Travere Therapeutics (formerly Retrophin)
  • 186. Rhythm Pharmaceuticals
  • 187. Ridgeback Biotherapeutics
  • 188. Rigel Pharmaceuticals
  • 189. Roche
  • 190. Sage Therapeutics
  • 191. Sagentia Innovation
  • 192. Sanofi
  • 193. Sanofi Genzyme
  • 194. Sarepta Therapeutics
  • 195. SCHOTT
  • 196. SCHOTT-KAISHA
  • 197. SCYNEXIS
  • 198. Seagen
  • 199. Servier Pharmaceuticals
  • 200. sfm medical devices
  • 201. Shandong Pharmaceutical Glass
  • 202. Shield Therapeutics
  • 203. Shionogi
  • 204. Shire Pharmaceuticals (acquired by Takeda)
  • 205. SIGA Technologies
  • 206. Simplivia
  • 207. SIPPEX
  • 208. SK Life Science
  • 209. SKINSORB
  • 210. Spark Therapeutics
  • 211. Spectrum Pharmaceuticals
  • 212. Sprout Pharmaceuticals
  • 213. Stemline Therapeutics (acquired by Menarini)
  • 214. Stevanato Group
  • 215. Strongbridge Biopharma
  • 216. Sun Pharma
  • 217. Sun Pharma Advanced Research Company (SPARC)
  • 218. Supernus Pharmaceuticals
  • 219. SYMATESE DEVICE
  • 220. Synergy Pharmaceuticals
  • 221. Taian Youlyy Industrial
  • 222. Taiho Oncology
  • 223. TaiMed Biologics
  • 224. Taisei Kako
  • 225. Takeda Pharmaceuticals
  • 226. Technoflex
  • 227. Terumo
  • 228. TESARO (acquired by GlaxoSmithKline)
  • 229. Tetraphase Pharmaceuticals
  • 230. Teva Pharmaceutical
  • 231. TG Therapeutics
  • 232. The Conference Forum
  • 233. The Feinstein Institutes for Medical Research
  • 234. The International Research Conference
  • 235. The Medicines Company (acquired by Novartis)
  • 236. The Metrix Company (formerly Riggs BioChemical)
  • 237. TherapeuticsMD
  • 238. Theravance Biopharma and Mylan
  • 239. Trevena
  • 240. Tyfill Pharmapack
  • 241. U.S. Food and Drug Administration (USFDA)
  • 242. UIHC - P E T Imaging Center
  • 243. Ultragenyx Pharmaceutical
  • 244. Unilife
  • 245. UCB
  • 246. United Therapeutics
  • 247. Unitract Syringe
  • 248. University of California, Los Angeles (UCLA)
  • 249. Urovant Sciences
  • 250. US WorldMeds
  • 251. Valmed Pharma
  • 252. VANDA Pharmaceuticals
  • 253. Vanrx Pharmasystems
  • 254. Verastem Oncology
  • 255. Vericel
  • 256. Vertex Pharmaceuticals
  • 257. Vetter Pharma
  • 258. Viela Bio (acquired by Horizon Therapeutics)
  • 259. ViiV Healthcare
  • 260. Vonlanthen
  • 261. Vygon
  • 262. Weibel CDS
  • 263. Wellstat Therapeutics
  • 264. West Pharmaceutical Services
  • 265. Wyeth
  • 266. Y-mAbs Therapeutics
  • 267. Ypsomed
  • 268. Yukon Medical
  • 269. Zealand Pharma
  • 270. Zionexa (acquired by GE Healthcare)